Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China · Delayed Price · Currency is CNY 25.78
+2.19 (9.28%)
May 29, 2026, 3:10 PM CST
SHE:300204 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Net Income | -83.86 | -77.76 | -144.84 | -398.89 | -197.01 | -137.4 |
Depreciation & Amortization | 23.72 | 23.72 | 22.78 | 32.31 | 33.99 | 36.8 |
Other Amortization | 0.56 | 0.56 | 0.08 | 0.14 | 0.07 | 0.12 |
Loss (Gain) From Sale of Assets | -0.88 | -0.88 | -0.28 | -0.3 | 0.04 | - |
Asset Writedown & Restructuring Costs | 2.06 | 2.06 | 0.08 | 10.55 | 25.36 | 3.52 |
Loss (Gain) From Sale of Investments | -0.14 | -0.14 | -0.14 | 0 | -4.05 | -20.82 |
Provision & Write-off of Bad Debts | -0.05 | -0.05 | -0.23 | - | - | - |
Other Operating Activities | -0.41 | -1.88 | -2.36 | 1.17 | 0.36 | 0.65 |
Change in Accounts Receivable | -61.69 | -61.69 | 27.62 | 126.6 | -83.75 | -148.12 |
Change in Inventory | -5.39 | -5.39 | -1.25 | -11.99 | 5.85 | 8.28 |
Change in Accounts Payable | -4.02 | -4.02 | -78.56 | -20.3 | 89.63 | 170.49 |
Operating Cash Flow | -130.31 | -125.68 | -63.68 | -228.32 | -175.6 | -162.07 |
Capital Expenditures | -88.39 | -76.63 | -23.53 | -32.15 | -56.51 | -56.24 |
Sale of Property, Plant & Equipment | 2.22 | 2.22 | 0.17 | 0.24 | 0.01 | 0.01 |
Investment in Securities | 19.28 | 21.42 | 27.57 | 49.75 | 371.25 | 175.86 |
Other Investing Activities | -0 | - | - | - | 6.57 | 23.02 |
Investing Cash Flow | -66.89 | -52.99 | 4.21 | 17.84 | 321.32 | 142.66 |
Short-Term Debt Issued | - | 80 | 46.36 | 60.14 | 22.94 | - |
Total Debt Issued | 148.85 | 80 | 46.36 | 60.14 | 22.94 | - |
Short-Term Debt Repaid | - | -30 | -45.16 | -42.69 | -0.67 | -48 |
Long-Term Debt Repaid | - | -0.17 | -0.06 | -0.47 | -2.62 | -2.5 |
Total Debt Repaid | -50.17 | -30.17 | -45.22 | -43.16 | -3.3 | -50.5 |
Net Debt Issued (Repaid) | 98.68 | 49.83 | 1.14 | 16.98 | 19.65 | -50.5 |
Issuance of Common Stock | 26.67 | 66.67 | 26.9 | 14.68 | 16.37 | 18.31 |
Common Dividends Paid | -1.73 | -1.09 | -0.54 | -1.02 | - | -0.32 |
Other Financing Activities | 113.08 | 133.23 | - | - | -3.4 | -3.4 |
Financing Cash Flow | 236.69 | 248.64 | 27.5 | 30.64 | 32.62 | -35.91 |
Foreign Exchange Rate Adjustments | -0.57 | -0.29 | 0.34 | 0.03 | 1.64 | -0.24 |
Net Cash Flow | 38.91 | 69.67 | -31.63 | -179.81 | 179.98 | -55.56 |
Free Cash Flow | -218.7 | -202.31 | -87.21 | -260.47 | -232.12 | -218.31 |
Free Cash Flow Margin | -107.25% | -91.86% | -26.85% | -71.52% | -42.28% | -37.36% |
Free Cash Flow Per Share | -0.46 | -0.42 | -0.18 | -0.55 | -0.48 | -0.46 |
Cash Income Tax Paid | 16.81 | 17.59 | 18.11 | 17.88 | 31.18 | 41.33 |
Levered Free Cash Flow | -163.39 | -144.06 | -54.02 | -159.73 | -190.16 | -150.29 |
Unlevered Free Cash Flow | -156.08 | -138.75 | -53.62 | -159 | -189.93 | -149.88 |
Change in Working Capital | -71.31 | -71.31 | 61.23 | 126.7 | -34.36 | -44.95 |